251. Increased risk of cervical cancer in high-risk families with and without mutations in the BRCA1 and BRCA2 genes
- Author
-
Rita K. Schmutzler, Christine Fischer, Kerstin Rhiem, K. Bosse, and Barbara Wappenschmidt
- Subjects
Cervical cancer ,Oncology ,Cancer Research ,education.field_of_study ,medicine.medical_specialty ,endocrine system diseases ,business.industry ,Population ,Cancer ,medicine.disease ,Standardized mortality ratio ,Germline mutation ,Relative risk ,Internal medicine ,medicine ,Cancer research ,First-degree relatives ,skin and connective tissue diseases ,Ovarian cancer ,education ,business - Abstract
5588 Background: In BRCA germline mutation carriers increased risks for cancer at other sites than breast and ovary have been reported. Methods: To evaluate the risk of BRCA-associated cancers, we conducted a cross-section analysis in 4405 individuals from 409 families with BRCA1 (n=86) or BRCA2 mutations (n=53) and 270 high risk BRCA1/2 negative families ascertained by the Familial Breast and Ovarian Cancer Center Cologne. We considered proven mutation carriers, individuals affected by breast and ovarian cancer and their first degree relatives and identified 921 individuals from BRCA1 (604 female; 317 male), 571 from BRCA2 (365 female; 206 male) and 2913 from BRCA1/2 negative (1938 female; 975 male) families that suffered from 677 cancers other than breast and ovarian cancers. Relative risks (RR) of the study group compared to the general population were evaluated by the standardized incidence ratio (SIR), using data from two German Cancer Registries. Results: The risk for cervical cancer is significantly increased in women from BRCA1 and BRCA2 positive (RR=4.59, 95% CI=2.20 to 8.44, and RR=3.69, 95% CI=1.20 to 8.61; p= No significant financial relationships to disclose.
- Published
- 2007